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nent summary (Wk24: 8.4 and 7.6; Wk48: 8.6 and 8.4) and mental component sum-
mary (Wk24: 5.5 and 3.5; Wk48: 4.8 and 3.2), PsAQoL (Wk24: -4.4 and -3.3; Wk48: -4.8 
and -3.5), and DLQI (Wk24: -6.3 and -5.2; Wk48: -6.2 and -5.6) for CZP 200mg Q2W 
and 400mg Q4W patients, respectively. ConClusions: Improvements in generic 
and disease-specific PROs observed over 24 wks were sustained over 48 wks in 
CZP-treated PsA pts. Improvements were observed regardless of CZP dose regimen.
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objeCtives: To develop a patient-reported outcome (PRO) instrument that can 
be qualified by the Food and Drug Administration (FDA) for use in rheumatoid 
arthritis (RA) randomized controlled trials (RCTs) to support treatment ben-
efit claims. Methods: On August 28, 2012, a consensus development workshop 
was held by the RA Working Group (WG) within the Critical Path Institute’s PRO 
Consortium to identify RA-related PRO concepts to determine their potential role 
in the documentation of treatment benefit in RA RCTs. Key stakeholders partici-
pated in this one-day meeting, including RA patients, representatives from the FDA 
(Division of Pulmonary, Allergy, and Rheumatology Products [DPARP] and Study 
Endpoints and Labeling Development [SEALD]), experts from the American College 
of Rheumatology (ACR), European League Against Rheumatism (EULAR), Outcome 
Measures in Rheumatology (OMERACT), National Institutes of Health (NIH, NIAMS) 
and the pharmaceutical industry (RA WG members). Results: Over the course of 
the workshop, a consensus emerged that there are several outcomes important to 
RA patients not explicitly assessed by the ACR response criteria (i.e., fatigue, stiff-
ness, and social participation). Finally, consensus amongst the various stakeholders 
was reached that any new measure needs to provide information over and above 
what is currently captured by the traditional primary composite endpoints and 
the priority would be to focus on FDA qualification of a PRO measure evaluating 
RA-related fatigue. ConClusions: The RA WG is initiating a collaboration with 
clinical experts through OMERACT to provide an operational definition of fatigue 
and to develop a conceptual framework to support its measurement in clinical trials. 
Following this preliminary step, qualitative and quantitative steps will be launched 
to develop the fatigue measure.
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Osteoarthritis (OA) is the most prevalent musculoskeletal disorder and has been 
associated with poorer quality of life for patients who experience heightened pain 
and decreased functionality. Despite the importance of OA management in clinical 
practice settings, there has been limited evidence confirming the adequacy of pain 
relief in patients with knee OA who take analgesics to manage their symptoms. 
objeCtives: To assess changes in pain relief states in the short run (30 days) and 
evaluate associated changes in outcome measures: SF-12, Brief Pain Inventory (BPI) 
and WOMAC in participants with knee OA. Methods: The Survey of Real World 
Therapies (SORT), a 12-month prospective study across 6 EU countries (N= 1,254), 
enrolled participants > 50 years old with knee OA who were prescribed analgesics. 
Patient-reported outcomes measures were collected at baseline and one month post 
baseline: BPI, SF-12 and WOMAC. Inadequate pain relief (IPR) was defined as BPI 
pain score of “moderate or greater pain” (> 4). Results: A total of 1153 participants 
were included: 67.3% women; mean age 68 years (SD= 9.4); mean OA duration 5.9 
years (SD= 6.2). 54% of participants reported experiencing IPR. After 30 days, 28% 
of participants reported changes in pain relief, which was equally distributed (14% 
each) between the two baseline pain-relief states. Changes in IPR states were sig-
nificantly associated with changes in SF-12 composite summary scores and WOMAC 
subscales. Patients who reported improvements in pain scores showed statistically 
significant improvements in average pain (2.7 points) and both QOL composite 
measures (p< 0.01): WOMAC subscales improvement ranged from 8-11 points and 
the Physical and Mental Component Summaries scores decreased 1.83 and 1.79 
points, respectively. Those who experienced worsening pain had an increase in aver-
age pain of 2.7 points on the BPI. These participants showed statistically significant 
decreases in QOL - WOMAC scores decreased between 4-9 points and PCS and MCS 
scores increased 2.10 and 2.27 points, respectively. ConClusions: Changes in pain 
states were significantly associated with overall quality of life and physical function.
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objeCtives: Osteoarthritis (OA), a degenerative condition of the articular cartilage, 
primarily affects the knee joint and surgery is often required for late-stage patients. 
The number of total knee arthroplasties (TKAs) is expected to grow to 3.48 million 
procedures by 2030 in the US alone. However, the devices lack an ideal safety profile. 
The objective of this study was to examine real-world outcomes among OA patients 
post-knee replacement. Methods: Data from the 2012 U.S. National Health and 
objeCtives: To evaluate the preferences of osteoporotic patients for medication 
attributes in Belgium and Ireland, and to assess whether preferences are transferable 
across these jurisdictions. Methods: A discrete-choice experiment was designed 
in which patients were asked to choose between two unlabelled drug alternatives 
(and an opt-out option), which vary in five attributes: efficacy in reducing the risk of 
fracture, type of potential common side-effects, mode and frequency of administra-
tion and out-of-pocket costs. An efficient experimental design was used to construct 
the sets of treatment options and a mixed logit panel data model was employed to 
estimate patients’ preferences. To assess the significance of the differences between 
countries, a joint model was estimated using interaction terms. Results: A total of 
257 Belgian and 200 Irish osteoporotic patients completed the experiment. In both 
countries, patients preferred a drug treatment with a higher risk reduction and a lower 
cost. They disliked more being at risk of gastro-intestinal disorders than at risk of 
skin reactions and flu-like symptoms and preferred 6-month subcutaneous injection 
compared with weekly oral tablets. In Belgium, patients also preferred oral monthly 
tablet over weekly tablets, while Irish patients preferred yearly intravenous over 
weekly tablets. Some differences between countries were significant. Irish patients 
attached higher value to being at risk for skin reactions or flu-like symptoms, and the 
parameter of yearly intravenous was higher (and significant) in Ireland. In addition, 
higher costs are more acceptable for Irish patients. These differences were generally 
robust in subgroups analyses including patients over 65 years, with prior fracture, high 
income or high education. ConClusions: In this study, the preferences of osteo-
porosis patients for drug therapy did not substantially differ between two European 
countries. Only for levels of some attributes significant differences were observed, 
which could not only be related to health and socio-demographic factors.
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objeCtives: To report the effect of certolizumab pegol (CZP), a PEGylated Fc-free 
anti-TNF, on patient-reported outcomes (PROs) in axial spondyloarthritis (axSpA), 
including ankylosing spondylitis (AS) and non-radiographic axSpA (nr-axSpA), over 
48 weeks (wks) in the RAPID-axSpA trial. Methods: The ongoing RAPID-axSpA trial 
(NCT01087762) is double-blind and placebo (PBO)-controlled to Wk24 and dose-blind 
to Wk48. Patient (pts) fulfilled ASAS criteria and had active axSpA. Pts originally 
randomized to CZP (200mg Q2W or 400mg Q4W, following 400mg loading dose at 
Wks 0, 2, 4) continued on their assigned dose in dose-blind phase; PBO pts enter-
ing dose-blind phase were re-randomized to CZP loading dose followed by CZP 
200mg Q2W or 400mg Q4W. We report efficacy data for the full analysis set (FAS) 
originally randomized to CZP. PRO endpoints included physical function (BASFI), 
total spinal pain, fatigue (from BASDAI), ASQoL, Sleep Problems Index II domain 
of MOS Sleep scale, and SF-36. Missing data were imputed by LOCF. Results: Of 
111 and 107 pts randomized to CZP 200mg Q2W and 400mg Q4W, 105(94.6%) and 
98(91.6%) completed the double-blind period, and 98(88.3%) and 93(86.9%) completed 
the dose-blind period. Rapid improvements from baseline to Wk24 were maintained 
to Wk48, for both CZP 200mg Q2W and 400mg Q2W, in total spinal pain (Wk24: -3.3 
and -3.2; Wk48: -3.6 and -3.5), fatigue (Wk24: -2.6 and -2.8; Wk48: -2.8 and -2.9), BASFI 
(Wk24: -2.4 and -2.3; Wk48: -2.6 and -2.4), ASQoL (Wk24: -5.1 and -5.1; Wk48: -6.0 and 
-5.6) and sleep (Wk24: -12.7 and -12.9; Wk48: -14.7 and -14.2). CZP-treated pts also 
maintained improvements in SF-36 components and domains. Similar outcomes 
were seen in AS and nr-axSpA populations. ConClusions: Improvements in PROs 
observed with both CZP dosing regimens were maintained over 48 wks, including 
those in pain, fatigue, physical function and HRQoL. Maintenance was observed in 
both AS and nr-axSpA pts.
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objeCtives: To report the effect of certolizumab pegol (CZP), a PEGylated Fc-free 
anti-TNF, on patient-reported outcomes (PROs) in psoriatic arthritis (PsA) over 
48 weeks (wks) in the RAPID-PsA trial. Methods: The ongoing RAPID-PsA trial 
(NCT01087788) is double-blind and placebo-controlled to Wk24 and dose-blind to 
Wk48. Patients (pts) had active PsA and had failed ≥ 1 DMARD. Pts originally rand-
omized to CZP (200mg Q2W or 400mg Q4W, following 400mg loading dose at Wks 
0, 2, 4) continued on their assigned dose in dose-blind phase; placebo pts entering 
dose-blind phase were re-randomized to CZP loading dose followed by CZP 200mg 
Q2W or 400mg Q4W. We report efficacy data for the randomised set (RS) of pts 
originally randomized to CZP. Mean changes from baseline in patient assessment of 
pain (VAS), fatigue assessment scale (NRS), HAQ-DI, SF-36, PsAQoL and Dermatology 
Life Quality Index (DLQI) were assessed with LOCF imputation. Results: Of 138 
and 135 pts randomized to CZP 200mg Q2W and 400mg Q4W, 128 (92.8%) and 120 
(88.9%) completed the double-blind period, and 123 (89.1%) and 114 (84.4%) com-
pleted the dose-blind period, respectively. Rapid improvements from baseline to 
Wk24 observed in double-blind period were maintained to Wk48 for pain (Wk24: 
-28.6 and -28.4; Wk48: -31.6 and -29.5), fatigue (Wk24: -2.2 and -1.9; Wk48: -2.4 and 
-2.0), HAQ-DI (Wk24: -0.52 and -0.43; Wk48: -0.56 and -0.49), SF-36 physical compo-
